Art. 29 Directive (EU) 2001/83

In forcesince 30 Apr 2004cited 43×
1.

If, within the period laid down in Article 28(4), a Member State cannot approve the assessment report, the summary of product characteristics, the labelling and the package leaflet on the grounds of potential serious risk to public health, it shall give a detailed exposition of the reasons for its position to the reference Member State, to the other Member States concerned and to the applicant. The points of disagreement shall be forthwith referred to the coordination group.

2.

Guidelines to be adopted by the Commission shall define a potential serious risk to public health.

3.

Within the coordination group, all Member States referred to in paragraph 1 shall use their best endeavours to reach agreement on the action to be taken. They shall allow the applicant the opportunity to make his point of view known orally or in writing. If, within 60 days of the communication of the points of disagreement, the Member States reach an agreement, the reference Member State shall record the agreement, close the procedure and inform the applicant accordingly. Article 28(5) shall apply.

4.

If the Member States fail to reach an agreement within the 60-day period laid down in paragraph 3, the Agency shall be immediately informed, with a view to the application of the procedure under Articles 32, 33 and 34. The Agency shall be provided with a detailed statement of the matters on which the Member States have been unable to reach agreement and the reasons for their disagreement. A copy shall be forwarded to the applicant.

5.

As soon as the applicant is informed that the matter has been referred to the Agency, he shall forthwith forward to the Agency a copy of the information and documents referred to in the first subparagraph of Article 28(1).

6.

In the circumstances referred to in paragraph 4, Member States that have approved the assessment report, the draft summary of product characteristics and the labelling and package leaflet of the reference Member State may, at the request of the applicant, authorise the medicinal product without waiting for the outcome of the procedure laid down in Article 32. In that event, the authorisation granted shall be without prejudice to the outcome of that procedure.

The 10 that are cited most themselves, of 43.

  • Directive (EU) 2004/27Lawamends

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecision

    In the course of those proceedings, the H igh Court of Justice of England and Wales, Queen’s Bench Division (Administrative Court) decided to stay the proceedings and refer the following questions to the Court for a preliminary …

    16 Oct 2008 · 62006CJ0452

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…13Law

    … в параграф 1 въпрос, по който не е постигнато съгласие, се прилага член 29, параграфи 3, 4 и 5 от Директива 2001/83/ЕО.

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decisioninterprets

    This request for a preliminary ruling concerns the interpretation of Articles 28 and 29 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human …

    14 Mar 2018 · 62016CJ0557

  • Gesetz über den Verkehr mit Arzneimitteln25b39Law

    … In diesem Fall hat die zuständige Bundesoberbehörde nach Maßgabe des Artikels 29 der Richtlinie 2001/83/EG zu verfahren. (3) Ist das Arzneimittel zum Zeitpunkt der Antragstellung noch nicht zugelassen, hat die zuständige …

  • Arzneimittelgesetz18aLaw

    … Anmeldung zur Registrierung ist, bereits registriert, so hat das Bundesamt für Sicherheit im Gesundheitswesen das in Artikel 28 und 29 Abs. 1 bis 3 der Richtlinie 2001/83/EG, in der Fassung der Richtlinien 2004/24/EG und 2004/27/EG, …

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    … zur gegenseitigen Anerkennung angerufen worden, weil einige Mitgliedstaaten einem Beurteilungsbericht in der in Art. 29 der Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung eines …

    11 Dec 2014 · 62013TJ0189

  • Judgment of the General Court (Ninth Chamber) of 26 January 2022. Mylan IRE Healthcare Ltd v European Commission.Decision

    … for annulment of Commission Implementing Decision C(2016) 2083 final of 4 April 2016 concerning, in the framework of Article 29 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for …

    26 Jan 2022 · 62016TJ0303

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    In the light of the foregoing, I suggest that the Court respond to the question posed by the Korkein hallinto-oikeus (Supreme Administrative Court, Finland) as follows: Article 28(5) and Article 29(1) of Directive 2001/83/EC of the …

    7 Dec 2017 · 62016CC0557

  • Judgment of the Court (First Chamber) of 9 June 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/03 to C-318/03) Decision

    Article 29(1) and (2) of that directive provide: ‘1. Where a Member State considers that there are grounds for supposing that the marketing authorisation of the medicinal product concerned may present a risk to public health, it shall …

    9 Jun 2005 · 62003CJ0211